Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
Purpose: Approximately 20% of patients with TP53-mutant myelodysplastic syndromes myelodysplastic syndromes:
Myelodysplastic Syndromes (MDS)
Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
Purpose: Patients with lower-risk (LR) myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-d
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?
The treatment of acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) has seen dramatic advances with the approval of multiple novel agents in recent years.
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
The utility of the International Working Group (IWG) 2006 response criteria for myelodysplastic syndromes myelodysplastic syndromes:
Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS)
Purpose: Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A gr
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
Purpose: Patients with lower-risk (LR) myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-d
Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes
Objective/background: Relapse is the most common cause of treatment failure after allogeneic hematopoietic cell transplantation (alloHCT). No standard of care exists, and a wide range of treatments are used for post-alloHCT relapse.
Current and emerging strategies for management of myelodysplastic syndromes
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
TP53 Modifier Impresses in Early MDS/AML Study
Original Publication Date
Article Source
External Web Content
A drug that targets a common mutation in myelodysplastic syndromes (MDS) led to historically high response rates as initial treatment for MDS and acute myeloid leukemia (AML), a small clinical trial showed. Overall, 71% of patients with TP53-mutant conditions responded to the…